AMENDMENT TO THE LICENSE AGREEMENT. Section 3.B of the License Agreement is hereby amended by adding the following sentence at the end thereof: “In the event that a product simultaneously falls within the definition of “Licensed Product” under this Agreement and the definition of “Royalty Product” under the CPI License Agreement: (a) Licensor agrees that any sale of such product will only implicate the payment of fees under one of the two agreements, not both (e.g., Licensor will not receive royalty payments both under this Agreement and the CPI License Agreement with respect to the same sale); (b) the Parties will determine which agreement will govern the fees to be paid to Licensor primarily by reference to the product’s actual intended use, and whether such use falls within the scope of the neuromodulation field of the Development Agreement or the “Implantable Cardiac Field” of the CPI License Agreement; and (c) if the Parties are unable to determine the governing agreement pursuant to clause (b) above, the Parties shall settle such disagreement pursuant to substantially the same mediation and arbitration provisions set forth in Section 4(E) and (F) of the CPI License Agreement with respect to a “Royalty Product Dispute” (as such term is defined in the CPI License Agreement) (it being understood and agreed that the scope of the arbitration will be limited to determining which agreement will govern the fees to be paid to the Company and that in no event will the Arbitrators have the power or authority to terminate this Agreement or the CPI License Agreement).
AMENDMENT TO THE LICENSE AGREEMENT. (a) Paragraph 1.9 is hereby added: “FIELD shall mean the diagnosis and/or treatment of (i) Attention Deficit Hyperactivity Disorder and (ii) Xxxxxxxxx’x Disease.
AMENDMENT TO THE LICENSE AGREEMENT. This Amendment to the License Agreement (the “Amendment”) is made as of January 31, 2017 (the “Amendment Effective Date”) by and between, IRONWOOD PHARMACEUTICALS, INC., a company organized and existing pursuant to the Laws of Delaware, and having its principal offices at 000 Xxxxxx Xxxxxx, Xxxxxxxxx, XX 00000, XXX (hereinafter, referred to as “Ironwood”) and ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD., a company registered in Ireland, whose registered office is at Clonshaugh Business & Technology Park, Coolock, Dublin, X00 X000, Ireland (the “Partner”).
AMENDMENT TO THE LICENSE AGREEMENT. Elan and JPI hereby agree that the License Agreement shall be amended as follows:
AMENDMENT TO THE LICENSE AGREEMENT. Section 18.6 of the License Agreement shall be deleted in its entirety and be replaced as follows:
AMENDMENT TO THE LICENSE AGREEMENT. THIS AMENDMENT (this “Amendment”) is entered into this 3rd day of May, 2004 (the “Amendment Date”), by and between Wyeth, a corporation organized and existing under the laws of the State of Delaware and having a principal place of business at Five Xxxxxxx Xxxxx, Xxxxxxx, Xxx Xxxxxx 00000, acting through its Wyeth Pharmaceuticals Division (“Wyeth”), and Cardiokine, Inc., a corporation organized and existing under the laws of the State of Delaware and having a principal place of business at 0000 Xxxxxx Xxxxxx, 0xx Xxxxx, Xxxxxxxxxxxx, XX 00000 (“Cardiokine”). Wyeth and Cardiokine may each be referred to herein individually, as a “Party” and collectively, as the “Parties”.
AMENDMENT TO THE LICENSE AGREEMENT. Section 14 of the License Agreement is hereby amended to add a new Section 14(r) to read as follows:
AMENDMENT TO THE LICENSE AGREEMENT. 2.1 The parties further agree to amend and restate Article 5 in its entirety as follows:
AMENDMENT TO THE LICENSE AGREEMENT. The following new “Section 11.11 Consent to Assumption” is hereby added to the License Agreement as follows:
AMENDMENT TO THE LICENSE AGREEMENT. (a) The parties acknowledge and agree that the following PCT application is hereby added to Item No. 7 on Revised Schedule A (Patent Rights) to the License Agreement: “[…***…]”
